Metformin vs. Rapamycin for longevity interest
Summary
Both are FDA-approved for other uses and attract off-label longevity interest. Neither is FDA-approved for aging. Metformin has a large trial (TAME) designed to test aging-related outcomes; rapamycin's longevity evidence is largely from animals.
At a glance
| Dimension | Metformin | Rapamycin (Sirolimus) |
|---|---|---|
| FDA-approved for | Type 2 diabetes | Transplant rejection; LAM |
| Longevity evidence in humans | Limited (observational; TAME trial designed) | Preclinical (mostly animal data) |
| Key risk | Rare lactic acidosis; B12 lowering | Immunosuppression; infection risk |
Metformin
- FDA-approved for
- Type 2 diabetes
- Longevity evidence in humans
- Limited (observational; TAME trial designed)
- Key risk
- Rare lactic acidosis; B12 lowering
Rapamycin (Sirolimus)
- FDA-approved for
- Transplant rejection; LAM
- Longevity evidence in humans
- Preclinical (mostly animal data)
- Key risk
- Immunosuppression; infection risk
What they have in common
- Both are used off-label by people interested in healthy aging.
- Neither has proven anti-aging benefit in healthy humans.
- Both require clinician oversight and monitoring.
Material differences
- Metformin has a long diabetes safety record; rapamycin is an immunosuppressant with more monitoring needs.
- Metformin's aging hypothesis is being tested prospectively (TAME); rapamycin's is not at that scale in humans.
Decision considerations
- That neither is FDA-approved for longevity.
- Your kidney function (metformin) or infection risk (rapamycin).
- The strength and limits of the current evidence.
- Monitoring that would be required.
Sources
- 1.TAME — Targeting Aging with Metformin — American Federation for Aging Research (AFAR). Professional organizationAccessed July 24, 2026.
- 2.A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug — PMC / NCBI (peer-reviewed review). Systematic reviewAccessed July 24, 2026.
- 3.RAPAMUNE (sirolimus) — Prescribing Information — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
- 4.Rapamycin for longevity: the pros, the cons, and future perspectives — PMC / NCBI (peer-reviewed review). Systematic reviewAccessed July 24, 2026.
Last reviewed (yesterday)